跳至主要内容
临床试验/NCT05848050
NCT05848050已完成不适用

Evaluation of the Humoral and Tumoral Molecular Alteration Profile of Brain Metastases

GCS Ramsay Santé pour l'Enseignement et la Recherche2 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2023年6月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
21
试验地点
2
主要终点
molecular alteration profile of liquid biopsies

研究概览

简要总结

The purpose of the study is to determine in brain metastases and according to feasibility in liquid biopsies:

  • Molecular alterations including in particular mutations, amplifications, Copy number gene variants and fusion transcripts identified by high-throughput sequencing;
  • The rate of variation either in gain or in loss of expression of the different messenger Ribonucleic Acids by analysis of the transcriptome;
  • Epigenetic alterations by methylation of deoxyribonucleic acid clusters by methylome chips.

详细描述

This is a single-center, prospective, interventional, exploratory study aimed at comparing the molecular alteration profile of liquid biopsies (blood and lumbar puncture) to that of brain metastases.

The population eligible for the study will consist of any patient with cerebral metastases from a solid cancer, at least one of which is accessible to surgical excision.

The study consists of comparing, between brain metastases and liquid biopsies (blood and lumbar puncture), the profiles of genomic, post-genomic and epigenetic alterations as well as the mutational load. To do this, the study only requires a lumbar puncture and a blood test.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient aged 18 or over;
  • Patient with cerebral metastases from a solid cancer, at least one of which is accessible to surgical excision (contrast enhancement of at least 1 cm);
  • Patient able to understand the information related to the study and to read the information leaflet;
  • Patient having signed a written informed consent to participate in the study.

排除标准

  • Patient with a medical contraindication to surgery and anesthesia;
  • Patient whose anatomical location of the cerebral metastasis contraindicates wide resection;
  • Patient with a contraindication to performing a lumbar puncture;
  • Pregnant, parturient or breastfeeding women;
  • Patient participating in another clinical trial, or in a period of exclusion from another clinical trial;
  • Patient under guardianship or curatorship, or under a regime of deprivation of liberty;
  • Patient not benefiting from a social security scheme.

结局指标

主要结局

molecular alteration profile of liquid biopsies

时间窗: 1 day

Compare the molecular alteration profile of liquid biopsies (blood and CSF) to that of brain metastases. Will be determined in brain metastases and according to feasibility in liquid biopsies (blood and CSF): * Molecular alterations including in particular mutations, amplifications, Copy number gene variants and fusion transcripts identified by high-throughput sequencing ; * The rate of variation either in gain or in loss of expression of the different messenger Ribonucleic Acids by analysis of the transcriptome ; * Epigenetic alterations by methylation of deoxyribonucleic acid clusters by methylome chips.

次要结局

未报告次要终点

研究者

发起方
GCS Ramsay Santé pour l'Enseignement et la Recherche
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验